ClinConnect ClinConnect Logo
Search / Trial NCT05837598

Adapting the Tumor Board Model for Mental Illness and Cancer

Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 26, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Cancer Care Major Depression And Cancer Schizophrenia And Cancer Bipolar Disorder And Cancer Lung Cancer Breast Cancer Head And Neck Cancer Gastrointestinal Cancer Genitourinary Cancer Schizophrenia Bipolar Disorder Major Depression Health Equity Mental Disorders

ClinConnect Summary

This clinical trial is looking at a new way to support patients who have both serious mental illnesses and a recent cancer diagnosis. Specifically, it tests a virtual tumor board, which is a group of doctors and mental health professionals who meet online to discuss and plan care for these patients. The goal is to see if this approach can improve patient care, help manage psychiatric symptoms, and boost the confidence of healthcare providers in treating these complex cases.

To participate in the trial, you need to be at least 18 years old, speak English well, and have a confirmed diagnosis of a serious mental illness like schizophrenia, bipolar disorder, or severe depression, along with a new diagnosis of certain types of cancer (like breast, lung, or gastrointestinal cancer). You also need to have seen a cancer specialist within the last two months. Participants will engage in the virtual meetings and will have their experiences and outcomes closely monitored throughout the study. This is an exciting opportunity to contribute to a better understanding of how to help individuals facing both mental health challenges and cancer.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥ 18 years old
  • 2. Verbal fluency in English
  • 3. SMI (schizophrenia spectrum disorder, bipolar disorder, or major depressive disorder with either prior psychiatric hospitalization, history of suicide attempt/suicidal ideation, Medicaid insurance, and/or comorbid alcohol or opioid use disorder) confirmed by diagnostic evaluation of study psychiatrist
  • 4. New invasive stage I-IV breast, lung, gastrointestinal, genitourinary, or head and neck cancer (highly suspected or confirmed according to documentation by the oncologist or pathology)
  • 5. Oncology consultation at or referral to a MGH Danvers within the past 8 weeks
  • Exclusion Criteria:
  • 1. Have cognitive impairment severe enough to interfere with completing brief study assessments or providing informed consent and does not have a guardian who can provide consent
  • 2. Recurrence of same cancer type
  • 3. Do not have verbal fluency in English

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Danvers, Massachusetts, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported